Table 5.
Overall survival and time-to-progression (n = 66)
| Characteristic | OS* (months) | 95% CI | 1-year survival rate (%) | P-value | TTP (months) | 95% CI | 1-year survival rate (%) | P-value | ||
|---|---|---|---|---|---|---|---|---|---|---|
|
Age |
<60 ≥ 60 |
26.0 25.0 |
18.9-33.1 14.2-35.8 |
69.2 69.9 |
.656 |
6.0 6.0 |
2.8-9.2 0.8-11.2 |
26.9 35.4 |
.611 |
|
|
Sex |
Male Female |
22.0 27.0 |
15.9-28.1 19.3-34.7 |
69.1 69.6 |
.134 |
6.0 6.0 |
0.0-14.2 2.7-9.3 |
28.0 34.6 |
.771 |
|
| Pancreas | 28.0 | 18.0-38.0 | 77.1 | .981 | 7.0 | 0.0-15.0 | 41.6 | |||
| Origin | GI | 22.0 | 0.0-46.9 | 63.2 | 2.0 | 0.8-3.2 | 25.0 | .258 | ||
| Lung | 9.0 | - | 50.0 | 1.0 | - | - | ||||
|
Liver metastasis |
Absent Present |
25.0 22.0 |
20.8-29.2 13.3-30.7 |
77.0 65.0 |
.310 |
12.0 4.0 |
9.2-14.8 1.3-6.7 |
40.7 23.8 |
.011 |
|
| 1 | 36.0 | 13.2-58.8 | 72.4 | 12.0 | 8.3-15.7 | 57.5 | ||||
| 2-3 | 17.0 | 1.1-32.9 | 53.0 | .612 | 4.0 | 1.2-6.8 | 34.3 | |||
| Grade | .681 | |||||||||
| Large | 12.0 | 0.0-29.8 | 50.0 | 2.0 | 0.0-4.5 | 45.0 | ||||
| Small | 17.0 | 10.1-23.9 | 100.0 | 12.0 | 2.6-21.4 | 30.0 | ||||
| 24-hour urine 5-HIAA (μmol/day) | <31.4 | 20.0 | 0.0-52.2 | 60.0 | .114 | 1.0 | - | - | .045 | |
| ≥ 31.4 | 40.0 | - | 62.5 | 12.0 | 0.0-29.6 | 44.4 | ||||
|
Biomarkers |
||||||||||
| Serum NSE (nmol/l) |
<1.0 ≥ 1.0 |
25.0 6.0 |
18.0-32.0 0.0-18.0 |
75.0 46.4 |
.170 |
2.0 4.0 |
0.9-3.1 1.2-6.8 |
0.0 22.2 |
.381 |
|
| IFN | 36.0 | 22.6-49.4 | 86.7 | .169 | 10.0 | 0.0-25.6 | 22.9 | |||
| Regimen | Somatostatin-analogue† | 3.0 | . | 50.0 | 0.0 | - | - | .057 | ||
| Chemotherapy | 20.0 | 13.3-26.7 | 64.5 | 6.0 | 3.6-8.4 | 34.2 | ||||
|
Treatment modality |
Systemic treatment only Systemic+local treatment |
23.0 29.0 |
0.4-45.6 23.6-34.4 |
57.9 86.1 |
.350 |
|||||
OS, overall survival; TTP, time-to-progression; CI, confidence interval; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon
*OS was estimated after initiation of systemic treatment except in treatment modality where OS was calculated after diagnosis of metastasis.
†Somatostatin-analogue was given to only 2 patients.